Source comparison
Marathon Runners BPC-157 Protocol: Dosing & Site Comparison
Achilles Tendinopathy 250–350mcg Subcutaneous, 2–3 inches proximal to tendon insertion Once daily 4–6 weeks Reduced morning stiffness, earlier return to easy running (typically week 3–4) Patellar Tendinitis Subcutaneous, medial or lateral to patellar tendon De
This comparison does not assign a generated winner or score.
- Achilles Tendinopathy
- 250–350mcg
- Subcutaneous, 2–3 inches proximal to tendon insertion
- Once daily
- 4–6 weeks
- Reduced morning stiffness, earlier return to easy running (typically week 3–4)
- Patellar Tendinitis
- Subcutaneous, medial or lateral to patellar tendon
- Decreased pain during eccentric loading, improved squat tolerance
- Plantar Fasciitis
- Subcutaneous, medial arch or heel fat pad
- Reduced first-step pain, faster resolution of morning heel pain
- IT Band Syndrome
- 250mcg per site
- Bilateral subcutaneous at lateral knee or distal IT band attachment
- Twice daily (split dose)
- Improved knee flexion tolerance, reduced lateral knee pain during hills
- Tibial Stress Reaction
- 350–500mcg
- Subcutaneous along medial tibial border near pain site
- 6 weeks minimum
- Gradual pain reduction, but requires concurrent load management
- Professional Assessment
- Standard protocols favor 250–350mcg daily for single-site injuries, split dosing (2×250mcg) for bilateral conditions. Injection proximity to injury matters. Subcutaneous administration within 5cm of damaged tissue maximizes local angiogenic effect. Cycle length should match one full collagen remodeling phase (4–6 weeks). Runners must reduce training load concurrently. Peptide accelerates repair but cannot overcome ongoing mechanical overload.